COVIran Barekat
A vial of COVIran Barakat | |
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Inactivated |
| Clinical data | |
| Other names | BIV1-CovIran[1] COVIran Barakat COVIran Barkat کووایران برکت |
| Routes of administration | Intramuscular |
| ATC code |
|
| Legal status | |
| Legal status |
Full and emergency authorizations Full list of COVIran Barekat authorizations |
| Identifiers | |
| CAS Number | |
COVIran Barekat[3] (Persian: کووایران برکت) is a COVID-19 vaccine developed in Iran by Shifa Pharmed Industrial Group, a subsidiary of the Barkat Pharmaceutical Group.[4][5][6] It is an inactivated virus-based vaccine.[3] Iranian authorities have authorized its emergency use. This makes it the first locally developed COVID-19 vaccine to be approved for emergency use in the Middle East.[7]
Officials in charge say they are in the process to publish the results of the clinical trials in a peer-reviewed journal.[8] The interim results of the phases 1 and 2 trials showed 93.5% (95% CI, 88.4–99.6%) of the receivers of the vaccine have produced neutralizing antibodies against SARS-CoV-2.[9] Those results have not been peer-reviewed and describe the immunogenicity of the vaccine and not its efficacy. On 3 March 2022, peer-reviewed results have been published in the Clinical Microbiology and Infection.[10]
As of February 27, 2022, approximately 60 million doses have been produced according to Shifa Pharmed's CEO.[11] and the annual production capacity of this vaccine has reached 350 million doses.[12] Multiple Iranian personalities have received the vaccine, including the Supreme Leader, Ali Khamenei[5] and the President, Ebrahim Raisi.[13]
A version of the vaccine based on the Omicron variant and named CovIran Barkat Plus is in development and studied to be given as a third dose.[14][15]
- ^ Cite error: The named reference
:10was invoked but never defined (see the help page). - ^ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
- ^ a b Mallapaty S (August 2021). "Iran hopes to defeat COVID with home-grown crop of vaccines". Nature. 596 (7873): 475. Bibcode:2021Natur.596..475M. doi:10.1038/d41586-021-02216-z. PMID 34404947. S2CID 237198729.
- ^ Motamedi M (29 December 2020). "COVIran Barakat: Iran launches human trials of its COVID vaccine". Al Jazeera. Archived from the original on 31 January 2021.
- ^ a b "Iran's leader gets locally made coronavirus vaccine shot". Reuters. 2021-06-25. Retrieved 2021-08-24.
- ^ "About - شرکت گروه صنایع شفافارمد". 2021-04-15. Archived from the original on 2021-09-03. Retrieved 2021-09-03.
- ^ Baghishov E (14 June 2021). "Iran issues license on its coronavirus vaccine". Trend.Az. Archived from the original on 2021-06-14. Retrieved 14 June 2021.
- ^ Cite error: The named reference
Tasnim_2021was invoked but never defined (see the help page). - ^ Setad (EIKO) (2021-06-16). "خلاصه نتایج تست انسانی واکسن کوو ایران برکت" [Summary of the results of COVIran Barekat vaccine's clinical trials] (PDF). Retrieved 2021-09-05.
- ^ Cite error: The named reference
:15was invoked but never defined (see the help page). - ^ "تولید ۶۰ میلیون دُز واکسن برکت در شفافارمد/ آغاز مطالعه بالینی واکسن اختصاصی اُمیکرون | خبرگزاری فارس" [Production of 60 million doses of Barakat vaccine in Shafafarmed / Initiation of clinical study of Omicron specific vaccine]. www.farsnews.ir (in Persian). 2022-02-26. Retrieved 2022-02-27.
- ^ The production capacity of the Barakat vaccine reached 350 million doses per year Tasnimnews.com, Retrieved 26 April 2022
- ^ Cite error: The named reference
:21was invoked but never defined (see the help page). - ^ "Iranian-made vaccine against Omicron begins clinical trial". Tehran Times. 2022-03-02. Retrieved 2022-03-03.
- ^ "IRCT | A Clinical trial to evaluate the immunogenicity and safety of Omicron-Based CovIran Barkat vaccine as a third injection dose in vaccinated population over 18 years of age". en.irct.ir. Retrieved 2022-03-03.